Previous Close | 0.5164 |
Open | 0.5100 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1200 |
Day's Range | 0.4929 - 0.5300 |
52 Week Range | 0.4500 - 1.3600 |
Volume | |
Avg. Volume | 30,982 |
Market Cap | 46.259M |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0890 |
Earnings Date | Nov 10, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BELGRADE, Mont., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022. “We are pleased to have achieved our highest revenue quarter since the start of the pandemic. Our second quarter revenue increased 2% over the same prior year period, including 8% year-over-year growth
BELGRADE, Mont., July 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2022, before the open of the financial markets on Thursday, August 4, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference ca
BELGRADE, Mont., May 05, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022. “By building momentum in our business, underscored by first quarter revenue growth and the progress of our key strategic growth pillars, we are pleased with the promising start to 2022,” said Sean Brown